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Toll-like receptors (TLRs) are known to be expressed by innate immune response cells and to play a critical role in their activation
against foreign pathogens. It was recently suggested that TLRs have an important role in the crosstalk between neurons and glial
cellsinthecentralnervoussystem(CNS).TLRsignalingwasreportedtobeassociatedwithayin-yangeﬀectintheCNS.WhileTLR
signaling was linked toneurogenesis, it was also foundto be involved inthe pathogenesis ofneurodegenerative diseases. This paper
will focus on TLR signaling in glial cells in neurodegenerative diseases such as Alzheimer’s disease, prion diseases, amyotrophic
lateral sclerosis, and Parkinson’s disease. Understanding the pattern of TLR signaling in the glial cells may lead to the identiﬁcation
of new targets for therapeutic application.
1.Introduction
Toll-like receptors (TLRs) recognize conserved pathogen-
associated molecular patterns (PAMPs) of bacteria, viruses,
yeast, fungi, and parasites [1]. At least 13 TLR genes exist in
mammals, and functional ligands have been identiﬁed [2].
TLRs 1–9 are expressed in both mice and humans, whereas
TLRs 10–13 are expressed only in mice [3].
A tight control of the TLR pathway is essential for main-
taining homoeostasis, since overactivation of TLRs has been
linked to various infectious and inﬂammatory diseases. TLR
engagementleadstotheactivationofthetranscription factor
nuclear factor κB( N F - κB), which regulates the induction
of proinﬂammatory cytokines such as tumor necrosis factor
α (TNFα), Interleukin-1β (IL-1β), and Interleukin-6 (IL-
6). It can also activate members of the mitogen-activated
protein kinase (MAPK) family including p38 and c-Jun N-
terminal kinase (JNK) [3]. These kinases are involved in the
transcription of genes and regulate mRNA stability. A tight
regulation of these pathways results from post-translational
modiﬁcation processes.
ActivationofTLR-mediatedsignalingbyvariousagonists
doesnotalwaysinvolveastraightforwardlock-and-keymode
of ligand-receptor binding. The extracellular domains of
all TLRs share important structural features, yet mediate
responsestowidelydiﬀerentagonists,pointingoutthatmore
complex interactions are involved. Many additional proteins
are required for the activation of TLR-mediated signaling by
their agonists, including coreceptors and docking molecules
on the cell surface and binding catalysts that promote certain
interactions, such as heat shock proteins [4–6]. In addition
to the essential contribution by coreceptors and accessory
interaction partners, most TLRs also operate as homo- or
heterodimers.
2.TLRSignalingPathways
TLRs are type 1 transmembrane glycoproteins characterized
by the presence of a leucine-rich repeat (LRR) domain and
a Toll/IL-1 receptor (TIR) domain [7]. LRRs are found in
a diverse number of proteins and are involved in ligand
recognition and signal transduction [8]. The intracellular2 Mediators of Inﬂammation
TIR domain portion consists of approximately 200 amino
acids and contains sequences that are highly conserved
among family members. TLRs are proposed to dimerize
following ligand binding, resulting in the recruitment of
TIR domain-containing adaptor molecules to initiate down-
stream signaling through interactions within the TIR regions
[9].
ThefamilyofTLRssharestructuralpropertiesofnotonly
their extracellular LRR structures but also their intracellular
domains, which interact with intracellular adaptor proteins
that relay the agonist engagement signal. Currently, ﬁve such
adaptors are known. The dominant and founding member
of this family of adaptors is myeloid diﬀerentiation factor
88 (MyD88), which relays the signal for most TLR family
members and tends to predominantly induce an NF-κB-
mediatedactivationofgenes,includingthoseencodingTNF-
α, chemokine (C-C motif) ligand 5 (CCL5 or RANTES),
IL-1β, and chemokine interleukin 8 (IL-8; CXCL8). The
less dominant adaptors are MyD88 adaptor-like protein
(Mal), TIR domain-containing adaptor inducing interferon-
β (TRIF),andTRIF-relatedadaptorprotein(TRAM).Recent
evidence indicates that TRIF associates with TRAF6 and
induces NF-κB signaling toward cytokine and chemokine
production [10]. The ﬁfth TIR adaptor SARM (sterile-α
and HEAT/Armadillo motifs-containing protein) has been
shown to inhibit TRIF [11].
TLR signaling may lead to diﬀerent responses in distinc-
tive cell types through an interaction with MyD88 unique
variants. Not every cell expresses the same set of adaptors.
For example, it is rapidly becoming clear that a selective
expression of the less-frequently used type of MyD88 in
neurons, renders these cells uniquely sensitive to TLR-
mediatedactivationoftheJNKpathwaytoapoptosis, instead
the NF-κB pathway towards inﬂammatory response as in glia
cells. In this way, selective expression of adaptors strongly
inﬂuences the quality of the response mounted by diﬀerent
types of cells to a given TLR agonist.
TLR4 was the ﬁrst TLR to be identiﬁed as an orthologue
of Drosophila Toll [12, 13]. Structures of TLR2, 3, and
4 with their ligands have been recently elucidated and
provide an understanding of ligand-induced activation of
TLRs [14–17]. All structures of TLRs bound to their ligands,
reveal a common “M”-shaped architecture. The C-termini
of the extracellular domains converge, therefore allowing
the interaction between TIR domains to occur and initiate
downstream signaling events [18].
TLR ligands encompass a broad spectrum of pathogens.
Each pathogenic ligand binds to a speciﬁc receptor, for
example: TLR2 plays an important role in the recognition of
fungal,gram-positive, and mycobacterialcomponents. TLR2
can form a complex with TLR1 or TLR6 and respond to
lipopeptides from a wide variety of microbes. The TLR1–
TLR2 dimer responds to triacylated lipopeptides, whereas
TLR2–TLR6 responds to diacylated lipopeptides. TLR3 rec-
ognizes double-stranded RNA (dsRNA). TLR4 is responsible
for the recognition of lipopolysaccharide (LPS) while TLR5
is responsible for the recognition of bacterial ﬂagellin [19].
Single-stranded RNA is recognized by TLR7 and TLR8,
and TLR9 recognizes DNA which can be either host or
pathogen derived [3]. TLR9 is associated with the cellular
response against bacterial cytosine phosphate guanosine
(CpG)DNA[20].Interestingly,severalTLRfamilymembers,
including TLR2 and TLR6, appear to cooperate in the
recognition of diﬀerent PAMPs in macrophages [21, 22].
For example, the TLR2-mediated response to phenol-soluble
modulin is enhanced by TLR6 but inhibited by TLR1,
indicating functional interactions between these receptors
[23].
3.TLRSignalingMediatesGlialCell
ActivationintheCNS
Innate immunity in the CNS depends primarily on the
functions of glial cells, especially astrocytes and microglia,
which are important for the early control of pathogen
replication,directrecruitment,andactivationoftheadaptive
immune system required for pathogen recognition and
clearance [24].
Under resting conditions, in rodents in vivo, TLRs 1–
9 have been detected in the CNS by quantitative real-time
PCR, with particularly strong expression of TLR3 [25]. The
levels of TLRs in the CNS can be upregulated by viral and
bacterial infection, treatment with TLR stimuli, or CNS
autoimmunity [25–28], providing a mechanism for ampli-
ﬁcation of inﬂammatory responses to pathogens infecting
the CNS. Human glial cells do not necessarily display the
same TLR proﬁle as rodent glial cells. Immunostaining
of cultured microglia and astrocytes for TLR3 and TLR4,
revealed two opposite features. Both TLR3 and TLR4 were
found exclusively localized in vesicular structures inside
microglia and not on the surface of the cells. However, with
cultured astrocytes, TLR3 and TLR4 were found only on the
cellular surface [26]. This striking diﬀerence in subcellular
localization of TLRs between microglia and astrocyte may
relate to the diﬀerence in phagocytic and antigen processing
properties of these cells [29–32].
3.1. TLR in Microglia. Microglial TLRs are crucial as a
ﬁrst line of defence against bacterial or viral infection.
In response to the appearance of multiple bacterial or
viral TLR agonists, TLR-mediated signaling promotes the
productionofavarietyofinﬂammatorymediators(reviewed
by [33, 34]). In addition, phagocytosis is stimulated by
TLR activation, which may be particularly relevant to the
c l e a r a n c eo fb a c t e r i aa sw e l la sa g g r e g a t e do ra b n o r m a l
proteins such as amyloid ﬁbers from the CNS [35, 36]
(Figure 1). Like other macrophage-like cells, microglia can
express essentially all diﬀerent TLR family members. While
TLR expression is hardly detectable in resting microglia in a
healthy CNS, multiple TLRs rapidly appear upon activation
of the cells. Primary microglia in vitro constitutively express
a wide array of TLRs (TLRs 1–9) at varying levels [26, 37].
ConstitutiveexpressionofTLRsisprimarilyinmicrogliaand
largely restricted to the circumventricular organs (CVOs)
and meninges, areas with direct access to the circulation,
although they may be expressed at lower levels in other
regions, too [28, 38, 39]. This unique localization allowsMediators of Inﬂammation 3
the CNS to recognize pathogens which are present in
the periphery as well as those that invade the CNS. Like in
macrophage, TLRs are exclusively found within endosomal
vesicles of microglia, illustrating their primary role in
examining the phagocytosed debris. While microglia express
all TLRs at readily detectable levels [26], TLRs 1–4 are the
most dominant, with TLR2 being the most highly expressed
TLR compared to other family members; this applies to
microglia in rodents as well as in humans. Lehnard et al. [40]
have indicated that microglial cells are the major cell type
that expresses TLR4 in the mouse brain.
Exogenous and endogenous TLR ligands activate
microglial cells. TLRs may mediate diﬀerent pathways in
microglia leading to either neuroprotective or neurotoxic
phenotypes. The activation of microglia with peptidoglycan
as TLR2 ligand [35], LPS as agonist for TLR4 [41], or
TLR9 ligand CpG [42], markedly boosted the ingestion of
Alzheimer’s disease neurotoxic Amyloid β (Aβ) protein in
vitro. A recent report [43] showed an enhanced phagocytic
ability of microglia toward amyloid protein as well as
cognitive improvement with the administration of a low
dose of CpG as an agonist for TLR9. Moreover, this group
emphasized that the clearance was not followed by the
release of nitric oxide (NO) and glutamate as neurotoxic
mediators.
However, activated microglia with TLR ligands also
produce neurotoxic molecules such as proinﬂammatory
cytokines, NO, reactive oxygen species (ROS), and peroxyni-
trite [44]. In particular, LPS-activated microglia produce a
large amount of glutamate, an important neurotransmitter
but also a potent neurotoxin [45] and LPS injection may
activate TLR4 on microglia and is linked to oligodendrocyte
injury [40].
3.2. TLR in Astrocyte. Primary murine astrocytes express a
wide variety of TLRs, but at lower levels than microglia,
suggesting that astrocytes may be important for antiviral
responses in the CNS. Expression of TLRs 1–9 was found on
surface of murine astrocytes. Furthermore, murine astrocyte
seems to express under physiological condition high levels of
TLR3 [46, 47]. To date, human astrocytes have been reported
to express TLRs 1–5 and TLR 9 [26, 48, 49]. The lack of TLRs
6–8maybeduetoadiﬀerencebetweenspeciesortheresultof
varyingisolationandcultureconditions.TLRs2–4areclearly
detectable on astrocyte in both cell culture models and in
vivo during trauma or inﬂammation [48–50].
TLR signaling in astrocyte can activate the production
of a wide range of neuroprotective and anti-inﬂammatory
mediators rather than merely stimulating proinﬂamma-
tory factors. Like microglia, a healthy human CNS barely
expresses TLRs on astrocyte, but once inﬂammation devel-
ops, TLR expression emerges on the cell surface of astrocyte,
detectable by immunohistochemistry [26].
The preference of astrocyte to express up to 200-fold
elevated levels of TLR3 upon activation is puzzling since the
only currently known ligand for TLR3 is dsRNA, which is
believed to emerge as an intermediate during viral replica-
tion. Yet, dsRNA is generally inside cells rather than secreted
into the microenvironment, and its detectable presence in
the microenvironment of CNS cells is rare. Bsibsi et al.
[48] have demonstrated that the TLR3-mediated response in
human astrocyte is far more comprehensive than the TLR4-
mediated response. TLR3-mediated activated astrocyte pro-
duce a variety of factors that are well-known mediators of
both neuroprotection, such as ciliary neurotrophic factor,
neurotrophin-4, and vascular endothelial growth factor, and
anti-inﬂammatory cytokines, such as TGF-β, IL-10 and IL-
11. Indeed, when poly I:C, an agonist for TLR3, is added to
organotypic human brain slice cultures, survival of neurons
signiﬁcantly improves [48].
Astrocyte take much longer than microglia to either
upregulate TLRs or produce cytokines and growth factors
in response to TLR activation. Moreover, TLR3-mediated
activation of astrocyte leads to a strong induction of
indoleamine 2,3-dioxygenase [50]. This enzyme converts
extracellular tryptophan into kynurenine, thereby reducing
its concentrations in the microenvironment, which in turn
markedly enhances the sensitivity of any nearby T-cell
for Fas-ligand-induced apoptosis [51]. In this way, the
TLR3-mediated induction of indoleamine 2,3-dioxygenase
i na s t r o c y t ea c t sa sal o c a li m m u n e - s u p p r e s s i v ef a c t o r[ 50].
3.3. TLR in Neuronal Cells. Accumulating evidence indi-
cates that TLRs play a role in tissue development, cellular
migration, diﬀerentiation, and repair processes, especially
in response to endogenous molecular ligands. Convincing
evidence indicates that neurons can express diﬀerent func-
tional TLRs, including TLRs 2, 3, 4, and 8 [52–58]. As in
other cells, expression levels are dynamic, and inﬂuenced
by soluble mediators including interferon-γ,o rb ye n e r g y
deprivation [56, 57, 59]. TLR3 was found to be expressed in
cultured human neurons following viral infection [60], and
on neurons in human brain tissue in cases of rabies or herpes
simplex virus infection [61].
Most TLRs, except TLR3, that are expressed in diﬀerent
cellssuchasglialcells,signalviathefoundingfamilymember
of the MyD88 family, which predominantly activates an NF-
κB-mediated response. The neuronal MyD88 variant, on
the other hand, associates with mitochondria, microtubules,
and JNK3, and regulates neuronal death during deprivation
of oxygen and glucose. Preferred expression of MyD88 in
neurons confers a diﬀerent quality of TLR responsiveness to
these cells as compared to cells such as glial cells that do not
express this MyD88 variant, but use other adaptors to relay
TLR-mediated signaling. As a consequence, TLR3, which
is concentrated in the growth cones of neurons, triggers
growth cone collapse [55]. TLR2 and 4 induce apoptotic
death[54],andTLR8inhibitsneuriteoutgrowthandtriggers
apoptosis [53]. In all these mentioned phenomena, signaling
pathways operate independently from NF-κB. Clearly, by
introducing diﬀerent MyD88 variants as the dominant
adaptor for TLR-mediated intracellular signaling, neurons
turn most TLR-mediated signals into negative signals for
growth, development, and even survival.
Engagement of TLR4 on neurons induces the expression
ofnociceptin,anopioid-relatedneuropeptide[58].However,
t h i sr e s p o n s ed i ﬀers from TLR4-mediated responses in many
other cells, in that neurons distinctly use the co-receptor4 Mediators of Inﬂammation
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Figure 1: Microglia TLR signaling in neurodegenerative diseases. Abnormal amyloid deposition in diﬀerent neurodegenerative diseases may
activate microglial cells through TLRs. Microglial activation may lead to further neuronal damage through secretion of proinﬂammatory
cytokines (green), such as IL-6 and TNF-α, or to neuroprotection by secretion of anti-inﬂammatory cytokines (blue), such as IL-10, which
maypreventfurtherneuronaldeath.Furthermore,recentreportssuggesttheroleofTLRs2,4,and9signalinginmodulatingthephagocytosis
(red) and clearance of the neurotoxic amyloid deposition.
MD-1, instead of the routinely used MD-2, along with
CD14 as interaction partners for binding the TLR4 agonist
LPS. This illustrates that neurons actually modulate the
TLR-signaling platform by not only introducing unusual
intracellular adaptors for unique signaling pathways, but
also by employing uncommon surface coreceptors, which
modulate the response.
4.TLR SignalingLinkto Neurotoxicity
Although the stimulation of TLRs on glial cells activate func-
tions that are important for the elimination of pathogens,
thesesamefunctionscanbetoxictocellsoftheCNSthathave
limited regenerative capacity. LPS exposure causes profound
microglial activation associated with oligodendrocyte death,
demyelination, and increased vulnerability of neurons to
injury, dependent on TLR4 signaling [40, 62]. Similarly,
microglia exposed to group B streptococcus (GBS) or S.
pneumoniae serotype 2 also display neurotoxic properties,
dependent on TLR2 [63, 64]. Some reports have demon-
strated that LPS-stimulated astrocytes are also neurotoxic,
while others have shown that only microglia are required for
toxicity [40, 65]. Toxicity appears to be mediated primarily
via NO. Indeed, pharmacologic blockade of iNOS is able
to prevent neuronal death in the presence of activated glia
[64, 65] and to rescue substantia nigra neurons from death
[66].
Stimulation of astrocytes with TLR ligands also inhibits
their ability to uptake excess glutamate [65, 67], and
therefore the role of astrocyte in neurotoxicity may be more
criticalinmodelsinwhichglutamateexcitotoxicityisamajor
mechanism of death.
Injection of poly I:C or Pam3CysSK4 into the CNS can
cause neurodegeneration in a TLR3- or TLR2-dependent
manner,respectively[63,68].LocalinjectionsofLPSdirectly
into the CNS cause severe loss of dopamine neurons in the
substantia nigra [69] and neurons in the hippocampus [70].
Newborn neurons in the hippocampus and dopaminergic
neurons in the substantia nigra appear to be extremely
sensitive to the eﬀects of LPS, as peripheral injection of
even low levels of LPS reduces the number of these cells
[71, 72].Mediators of Inﬂammation 5
5.TLR SignalingLinkto Neurogenesis
Neurogenesis is the process by which new neurons are
created from neural progenitor cells in the adult brain. It
occurs in two major brain regions—the subventricular zone
(SVZ) and the dentate gyrus (DG) of the hippocampus
[73]. The mechanisms for neurogenesis are emerging with
time. Recent evidence suggest that neural progenitor cells
also express TLRs [53, 74]. Rolls et al. [74]h a v ep r o -
posed that since TLR2 is widely expressed in the brain,
and in cells that express early neuronal markers, they
may be involved in adult hippocampal neurogenesis. They
have demonstrated that in TLR2-deﬁcient mice, there is
a reduction in the diﬀerentiation of neural progenitor
cells into neurons, and an increase in the diﬀerentiation
into astrocytic cells, and that TLR2 activators increased
diﬀerentiation. The increase in diﬀerentiation was mediated
through the NF-κB pathway. In addition, TLR4 has been
found to be involved in proliferation via both MyD88-
dependent and MyD88-independent pathways. A TLR4 deﬁ-
ciency caused an increase in proliferation and diﬀerentiation
[74].
TLR8 is dynamically expressed during mouse brain
development and localizes to neurons and axons where it
may regulate neurite outgrowth and apoptosis [53]. TLR2
and TLR4 are expressed in adult neural progenitor cells
and may inﬂuence the proliferation and diﬀerentiation [74].
Some TLRs are strongly expressed in the embryonic brain
and TLR3 and TLR8 have been implicated in neurogenesis
andneuriteoutgrowthinthedevelopingbrainwhereasTLR2
and TLR4 have been shown to regulate adult neurogenesis
[75, 76].
In embryonic development, TLR3 negatively regulates
neural progenitor cell diﬀerentiation [77]. It has also been
suggested recently that in the adult brain TLR3 mediates
the production of anti-inﬂammatory and neuroprotective
factors,andthusaTLR3activationmaypromotecellsurvival
[48]. TLR8 is a suppressor of murine neurite outgrowth and
induces neuronal apoptosis, through an NF-κB independent
mechanism. [59]
6. TLRSignalinginNeurodegenerativeDiseases
A dysfunction of glial and neuronal receptors, which alter
the cells sense of their environment, can lead to neurode-
generative diseases. Therefore, the role of TLRs in mediating
cell response to stress conditions may play a crucial role in
neurological disease progression, as can age-related changes
in cell division. Targeting speciﬁc TLR signaling may allow
the maturation and function of glial and neuronal cells to
aid in neuronal repair.
6.1. Alzheimer’s Disease. Alzheimer’s disease (AD) is a pro-
gressiveneurodegenerativedisease,characterizedbyprogres-
sivememorydeﬁcits,cognitiveimpairments,andpersonality
changes. The histopathological hallmarks include deposition
of Aβ, neuroﬁbrillary tangles (NFTs), progressive synaptic
dysfunctionand,muchlater,neuronaldeath,especiallyinthe
hippocampus [78–80].
While the role of inﬂammation in disease progression in
AD is not fully understood, an increased amount of ﬁndings
suggest that Aβ deposition and NFT activate a potentially
pathological innate immune response in the disease [81].
Aβ plaques are surrounded and inﬁltrated by activated
astrocytes and microglia, which are believed to be the major
source of local inﬂammatory components [82].
An increasing amount of data is emerging that describes
the involvement of TLRs in the pathogenesis of AD. The
ﬁrst line of evidence shows an increased expression and
upregulationofdiﬀerentTLRgenesandTLR-relatedgenesin
AD patients and mouse models. For example, the expression
level of TLR2 and TLR7 is higher in APP transgenic mice,
which accumulate Aβ deposits in their brain, then their
matched controls, at 6 months of age [83].
An examination of TLR expression in the brain revealed
that there was increased expression of CD14, TLR2, and
TLR4 in AD human brains and animal models [41, 84–86].
Plaque-associatedmicrogliaexhibitelevatedmRNAlevelsfor
TLR2, 4, 5, 7, 9 [87]( Figure 1). An injection of Aβ into
the hippocampus provokes TLR2 gene expression [88]. It
is of interest that a polymorphism in TLR4, which results
in a blunted signaling response corresponds to a 2.7-fold
reduction in risk for late-onset AD [89].
Fiala et al. [90] have reported that upon Aβ stimu-
lation, mononuclear cells of normal subjects up-regulate
the transcription of β-1,4-mannosyl-glycoprotein 4-β-N-
acetylglucosaminyltransferase (MGAT3) (Figure 1). The
downstream eﬀect of MGAT3 on phagocytosis may depend
upon TLRs and indeed, there was an upregulation following
TLRs activation. Interestingly, mononuclear cells of AD
patients generally have downregulated MGAT3 and TLR
genes as compared to normal individuals. Furthermore,
ad e f e c t i v ep h a g o c y t o s i so fA β may be related to the
downregulation of MGAT3, as suggested by an inhibition of
phagocytosis using MGAT3 siRNA [90].
Another line of evidence suggests that in AD there is
a form of TLR dysfunction that appears in TLR4, which
is localized on the surface of microglial cells (Figure 1).
A loss-of-function mutation in TLR4 inhibits microglial
cell activation towards Aβ depositions, which results in
a decrease in the amount of proinﬂammatory cytokines
IL-6 and TNF-α and NO. TLR4 has also been found to
contribute to Aβ-induced microglia neurotoxicity. A tri-
molecular complex consisting of TLR4, MD-2, and CD14
has to be complete for full cellular stimulation by aggregated
Aβ. There is also an elevated level of TLR4 in transgenic APP
mice and in the brains of AD patients. [86].
Tahara et al. [36] have shown that TLR4 loss-of-function
mutation in APP transgenic mice increase diﬀuse and
ﬁbrillar Aβ deposition without an increased expression of
APP, and that uptake of Aβ is reduced in TLR4 mutant
microglia. They have also demonstrated that the activation
of TLR 2, 4, and 9 increased clearance of Aβ [36, 42].
Balistreri et al. reported that a TLR4 polymorphism is
involved in aging, and in some age-related diseases such as
AD [91]. The phenotypes are associated with changes in
cytokine expression. One such haplotype has reduced the
production of proinﬂammatory cytokines [92]. AD patients6 Mediators of Inﬂammation
in the Italian population had an increased frequency of the
proinﬂammatory haplotype [91].
Lotz et al. [93] showed that coadministration of Aβ
1–40 with TLR2 or TLR4 agonists, Pam3-cys and LPS,
respectively, led to an additive release of NO and TNF-α.
However, coadministration of Aβ 1–40 with TLR9 agonist
CpG, led to a decrease in the release of NO and TNF-
α. This suggests that not all TLR agonists enhance the
stimulatory eﬀect of Aβ on innate immunity [93]. In
microglia (Figure 1), the TLRs functionally interact with
other cell surface receptors, including CD36, α6β1 integrin,
CD47, and scavenger receptor A, which bind to ﬁbrillar Aβ,
to initiate the activation of intracellular signaling pathways
[94, 95].
6.1.1. Targeting TLR as Therapeutic Application in AD. APP
mouse models with a TLR4 deﬁciency have an increase in
insoluble Aβ in the cortex, as compared to TLR4 wild-
type APP mouse models [36]. Thus, factors that increase
the microglial cell clearance of Aβ, without producing
inﬂammatory mediators, are candidates for the treatment of
AD (Figure 1).
These results suggest that the TLR signaling pathways
may be involved in the clearance of Aβ deposits in the brain
and that TLRs can be a therapeutic target for application
in AD [36]. Indeed, it was shown that an injection to the
intrahippocampus of LPS derivatives (a TLR4 ligand) to the
brains of AD mice reduced Aβ load, suggesting that the
activation of microglia by TLR4 may be therapeutic in AD
[96].
Bisdemethoxycurcumin is a natural curcumin, a minor
constituent of turmeric (curry), that enhances phagocytosis
and the clearance of Aβ in cells from most AD patients,
and increases transcription of the MGAT and TLR genes
[97]. Furthermore, administration of CpG, a TLR9 activator,
in APP transgenic mice, resulted in clearance of Aβ from
microglial cells [42].
In conclusion, TLR activation may modulate glial cell
activity in AD. Recent research suggests the involvement of
TLRs 2, 4, 5, 7, and 9 in the proinﬂammatory response of
microglia toward Aβ, which may be linked to neurotoxicity
(Figure 1). Nevertheless, the activation of TLRs 2, 4, and
9 were also linked to both phagocytosis of the neurotoxic
Aβ and to an anti-inﬂammatory response (TLR9), which
may lead to neuroprotection (Figure 1). Therefore, elevated
expression levels of TLRs 2, 4, and 9, through genetic
modiﬁcation or toward speciﬁc agonists, may be a thera-
peutic application in AD. Indeed, a recent publication [98]
suggests the use of TLRs 2 and 4 agonist as a speciﬁc
macrophage activator to increase the clearance of Aβ in an
AD mouse model. An alternative therapeutic approach may
be the reduction of TLR5 and 7, by using shRNA or speciﬁc
antagonists (Figure 1).
6.2. Prion Diseases. Prions are infectious particles that are
composed mainly of proteins. In prion diseases, prions
create extracellular aggregates of beta-sheet-rich, misfolded
form, in diﬀerent tissues, such as the spleen, muscles, and
brain. In the brain, aggregated prions are presented by
neurons, followed by neurodegeneration. Prion diseases are
characterized by their transmissibility and are therefore also
termed transmissible spongiform encephalopathies (TSE).
Prion diseases have occurred in humans and animals for
many years. The human prion disease is Creutzfeldt-Jakob
disease (CJD) [99]. All known prion disease aﬀect the
structureofthebrainwithneuropathologicalfeaturessuchas
neuronal loss, astrocytic activation (gliosis), and spongiform
change, and all are currently untreatable and fatal [100].
Prions have a role in the activation of the innate immu-
nity, which suggests functional and structural similarities
withDrosophila Tollreceptors [101].Themice withmutated
TLR4, wherein signaling is prevented, developed Prion
disease in a shorter period of time than control mice, but
did not exhibit diﬀerent levels of prions. This indicates an
involvement of TLR4 in the progression of the disease [102].
In addition, in human patients with CJD, there is an elevated
level of IL-10, which has been suggested to have a protective
role in the disease. TLR4 signaling induces IL-10 production,
and this may be the pathway by which TLR4 dysfunction
may mediate the rapid progression of the disease [103, 104].
Nevertheless, MyD88 knockout mice inoculated with prions
have not shown diﬀerent prion pathogenesis kinetics from
the control mice, suggesting that TLRs 1, 2, 6, and 9 signal
through the MyD88 pathway and are not involved in the
progression of the disease [105, 106]( Figure 1).
6.2.1. Targeting TLR as Therapeutic Application in Prion
Diseases. It has been suggested that TLR9 expression may
be linked to the progression of prion diseases. Furthermore,
treatment with synthetic oligodeoxynucleotides that contain
cytosine phosphate guanosine (CpG-ODN) motifs, known
to bind to TLR9, have been suggested as possible treatment
for prion diseases in a mouse model, by delaying the disease
onset [105, 107]. Another explanation may be the eﬀect of
CpG-ODN on microglia activation that may lead to prion
degradation [108]( Figure 1). Furthermore, as the activation
of TLRs in other amyloidogenic diseases, such as AD, has
been linked to the clearance of neurotoxic amyloid, it may
prove to be a potential therapeutic approach to the prion
diseases.
6.3. Amyotrophic Lateral Sclerosis. Amyotrophic lateral scle-
rosis (ALS) is a devastating and chronic neurodegenerative
disease, characterized by selective loss of lower and upper
motor neurons [109]. Ten percent of ALS cases are familial
(fALS) with 20–25% of these cases resulting from various
mutations in the SOD1 gene [110]. The toxicity of the
mutant SOD1 (mSOD1) is again of function, because mice
that lack the gene do not develop the disease [111], and may
be a noncell-autonomous progression [112]. One proposed
mechanism for pathogenesis is the aberrant oligomerization
of mSOD1 proteins in beta-sheet form, that can be stained
by thioﬂavin S [113].
Several studies have demonstrated the involvement of
microglia in ALS pathogenesis (Figure 1). For example,
microglia with mSOD1 release more superoxide, nitrate andMediators of Inﬂammation 7
nitrite and induce more neuronal death [114]. It has also
been demonstrated that mSOD1 mice had an elevated level
of TLR1, 2, 7 and 9 at 8 months of age, as compared to the
matched age control group [83]. Treatment of mSOD1 mice
with wild-type microglia improved the pathogenesis [114].
Kang and Rivest [115] have demonstrated that mSOD1
activates microglia through the MyD88-dependent pathway,
and mice that were transplanted with bone marrow from
MyD88 knockout mice exhibited earlier disease onset and a
shorter life span. This suggests a crucial eﬀect of MyD88 in
an ALS mouse model. Nevertheless, there was no diﬀerence
in the disease onset and life span between mSOD mice with
MyD88 knockout and mice with normal MyD88. However,
MyD88 knockout mice had a more activated microglia at the
end stage of the disease, and they lost more motor neurons,
whichsuggeststhatthecontextofMyD88deﬁciencyislinked
to neurotoxicity.
Zhao et al. [116] have demonstrated that mSOD1 binds
to CD14, which has a role in the activation and toxicity
of microglia treated with extracellular mSOD1. CD14 is a
co-receptor of TLRs 2 and 4, and blocking the signaling of
both of these TLRs inhibited microglial activation following
extracellular mSOD1 administration. However, they have
found that CD14 knockout mice showed a similar disease
progression proﬁle as the control mice.
Nguyen et al. [117] activated the innate immune
response in mSOD1 mice. They injected systemic LPS,
which increased TLR2 expression across the brain and
spinal cord in both wild-type and mSOD1 mice, without
changing mSOD expression. Chronic systemic administra-
tion of LPS exacerbated disease progression and motor
neuron degeneration, which shortened life span. The degree
of TLR2 elevation showed a correlation to motor neuron
degeneration.
6.3.1. Targeting TLR as a Therapeutic Application in Amy-
otrophic Lateral Sclerosis. While some research suggests TLR
signalinghasanimportantroleinneurotoxicityinALS,there
is no clear evidence for a speciﬁc TLR that may mediate this
eﬀect. Further research should aim to distinguish between
elevated expression of diﬀerent TLRs in modulating an
inﬂammatory response in ALS and their role in disease
progression. A potential link between TLR signaling and an
increase in neurotrophic factor secretion from glial cells may
prove to be a therapeutic approach in ALS.
6.4. Parkinson’s Disease. Parkinson’s disease (PD) is a pro-
gressive neurodegenerative disorder characterized by resting
tremor, muscular rigidity, and gait disturbances [118, 119].
PD is pathologically characterized by the progressive loss
of dopaminergic neurons in the substantia nigra pars
compacta and their termini in the dorsal striatum [120]. The
pathological hallmark of PD is the presence of deposits of
aggregated α-synuclein in intracellular inclusions known as
Lewy bodies [121, 122].
One of the Parkinson’s disease animal models is com-
posed of an intranigral LPS injection, which stimulates
dopaminergic cell death [123]. In this model, microglial cells
are activated, and demonstrate an upregulation of proin-
ﬂammatorycytokinesandfreeradicalproduction[124,125].
LPS is a TLR4 activator, which suggests that there may be
a TLR involvement in the pathogenesis of PD. In an MPTP
mouse model of PD there was increased expression of TLR4
and CD14, suggesting an involvement of the TLR pathway in
the pathogenesis of PD [126].
6.4.1. Targeting TLR as Therapeutic Application in Parkinson’s
Disease. A recent paper showed that α-synuclein immuniza-
tion in a PD animal model may ameliorate disease pro-
gression [127]. Targeting mechanisms in which α-synuclein
activates TLR signaling, may open a new horizon for
therapeutic application in PD.
7. Conclusion
TLRs play an essential role in modulating self-defense in
diﬀerent types of species: from ﬂy to human. More recently,
it has been suggested that TLRs are important to both cell
development and cell-cell interaction. The complex of TLR
cascade may trigger speciﬁc pathways, which aﬀect the fate
of cell activation. The CNS is monitored by the BBB from the
peripheral immune response, and is dependent on glia sur-
veying for innate immunity. Abnormal amyloid depositions
in the CNS may mimic viral or bacterial infection, which
may trigger glial cell activation through TLRs. Investigating
the neurotoxic and neuroprotective mechanisms of TLR
signaling in glial cells may be crucial for understanding their
role in the pathogenesis of neurodegenerative diseases, and
may pave the route for future therapeutic intervention. Cur-
rently, targeting TLRs is being used in diﬀerent experimental
settings, from animal model experiments to clinical trials,
including several diseases, such as chronic lung disease and
cancer [128]. However, there are very few tests regarding
neurodegenerative diseases. We suggest that targeting TLRs
and TLR pathways may also be applicable as a possible
treatment for those diseases.
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